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MicroRNAs (miRNAs) regulate gene expression and may contribute to HIV-1 infection. In this study,
our goal was to investigate the mechanisms by which miR-34a inﬂuenced Tat-induced HIV-1 trans-
activation through the SIRT1/NFjB pathway. We showed that Tat induced up-regulation of miR-34a
expression in TZM-bl cells. MiR-34a signiﬁcantly inhibited SIRT1 expression. Overexpression of
miR-34a increased Tat-induced LTR transactivation. Forced expression of miR-34a decreased SIRT1
protein expression and consequently diminished Tat-induced acetylation of p65, while treatment
with a miR-34a inhibitor had the opposite effect. These results suggest that regulating SIRT1 by
down-regulation of miR-34a levels may be a therapeutic strategy against HIV-1 replication.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Several key HIV-1 and cellular proteins have been determined
to be necessary for a chronic persistent infection, including the
trans-activator Tat [1–3]. The replication rate of integrated HIV-1
is largely controlled at the level of transcription. Though viral tran-
scription is fully dependent upon host cellular factors, recent ﬁnd-
ings indicate a complex interplay between viral proteins and host
transcription and signaling machineries (i.e. histone deacetylasess
(HDACs), histone acetylases (HATs), and other protein-modifying
factors) [4–6]. Dynamic modiﬁcations of chromatin structure and
nucleosome remodeling have been implicated in HIV-1 transcrip-
tion [4]. HATs can acetylate Tat at lysines 28, 50 and/or 51, all of
which impart different functions. For instance, acetylation at lysine
50 and 51 by CBP/p300 and GCN5 promotes the dissociation of Tat
from the TAR-binding domain, indicating the start of transcrip-
tional elongation [5]. Human sirutin (SIRT1) is a class III histone
deacetylase (HDAC), which mediates de-acetylation of Tat.
De-acetylation occurs at the Lys residue at position 50. SIRT1 can
inhibit nuclear transcription factor-jB (NF-jB). As a master tran-
scription factor, NF-jB is proposed to be important mediators of
HIV-related transcription and replication [7].
There is increasing evidence that post-transcriptional regulation
of gene expression, mediated by microRNAs (miRNAs), plays an
important role in the control of cell proliferation, apoptosis,chemical Societies. Published by E
).tumorigenesis and virus infection [8–10]. Several studies have
proposed a regulation paradigm whereby cellular miRNAs target
mRNAs that encode cellular proteins involved in virus replication.
For example, the miR-17/92 cluster, which encodes seven miRNAs,
among which miR-17-5p and miR-20 may target HATs and HIV-1
Tat cofactor PCAF, was substantially decreased during HIV-1 infec-
tion [11]. MicroRNA-34a (miR-34a) is mapped in the region of chro-
mosome 1p36.23, and usually it is aberrantly expressed in multiple
types of diseases [12]. MiR-34a has many potential target genes,
including SIRT1, NMYC, CCND1, CCNE2, CDK4, CDK6, and MET [13].
In the study, we showed that upregulated miR-34a promoted
Tat-induced HIV-1 transactivation. We further demonstrated that
miR-34a directly targeted 30-UTR of SIRT1 gene. Importantly, SIRT1
re-expression reduced Tat-induced HIV-1 transactivation induced
by miR-34a.2. Materials and methods
2.1. miRNA target predications
Two algorithms, PicTar (http://pictar.mdc-berlin.de) andmiRan-
da (http://www.microrna.org) were used to predict putative bind-
ing sites in the SIRT1 mRNA for members of the miR-34a family.
2.2. Cell culture and reagents
TZM-bl is a HeLa-derived cell line expressing surface CD4,
CXCR4, CCR5 and containing a chromatin-integrated HIV-1 LTR.lsevier B.V. All rights reserved.
Fig. 1. miR-34a level was signiﬁcantly increased by Tat in TZM-bl cells and SupT1 T
cells. TZM-bl cells and SupT1 T cells. were transfected with (A) 20, 50, 100 Nm Tat
plasmid; (B) mimics control (pre-miR-control), miR-34a mimics (pre-miR-34a),
inhibitor control (anti-miR-control), miR-34a inhibitor (anti-miR-34a) or 100 nM
Tat plasmid for 48 h. Total RNA was subjected to real-time RT-PCR to analyze the
expression level of miR-34a in each sample. U6 was used as a reference for miRNAs.
Relative miR-34a level of each sample was calculated with respect to the normal
control. Each sample was analyzed in triplicate. ⁄⁄P < 0.01(compared to control). ##
P < 0.01(compared to Tat).
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mented with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomy-
cin, 200 lg/ml G418, and 100 lg/ml hygromycin B at 37 C in 5%
CO2 and 95% air in humidiﬁed atmosphere. The human lympho-
cytic cells, SupT1 T cells were grown in RPMI 1640 medium
supplemented with 10% fetal calf serum at 37 C and 5% CO2.
Nicotinamide (NAM), phorbol 12-myristate 13-acetate (PMA) and
Trichostatin A (TSA) were purchased from Sigma (St. Louis, MO).
The following polyclonal antibodies: anti-p65, anti-SIRT1, and
anti-b-actin were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-Ac-p65 (Lys 310) antibody was purchased from
Abcam (Cambridge, MA). The secondary antibodies IR800 anti-
rabbit, IR800 anti-goat and IR800 anti-mouse IgG were obtained
from Li-COR Biosciences (Lincoln, Nebraska, USA). The pCI-Tat
plasmid was kindly provided by Prof. Ping-Kun Zhou (Beijing Insti-
tute of Radiation Medicine, Beijing). The SIRT1 and SIRT1 H363Y (a
deacetylase-defective mutant of SIRT1) expression plasmids were a
gift from Dr. Kouzarides (Cancer Research UK Gurdon Institute,
Cambridge). All other chemicals were of the highest commercial
grade available.
2.3. Cell transfection
For all transfections, TZM-bl cells were used at a conﬂuence of
50–60%. Typically, cells were transfected with Tat plasmid per
well in a 6-well dish by using Genejuice transfection reagent as
we previously described [14]. Cell extracts were prepared 48 h
after transfection. SupT1 T cells were performed by transfecting
with Tat expressing plasmid and HIV-1 LTR: luciferase plasmid
[15].
MiRNA mimics and miRNA inhibitors were designed and syn-
thesized by GenePharmar (Shanghai, China). MiRNA inhibitors
were designed such that all the nucleotides contained a 20-O-
methyl modiﬁcation. Twenty-four hours prior to transfection, cells
were plated onto a 6-well plate (Greiner, Germany) at 40–60%
conﬂuence. Transfection of TZM-bl cells grown in 6-well plates
were performed using 20 nM miR-34a mimics or negative control,
50 nM miR-34a inhibitor or negative control, and 1 ll of Lipofect-
amine 2000 (Invitrogen, USA), according to the manufacturer’s
instructions [16]. For miR-34a assay and western blot analysis,
cells were harvested for RNA and protein respectively after 24–
48 h.
2.4. Real-time polymerase chain reaction (PCR)
Real-time PCR was performed as previously described [17].
2.5. Luciferase reporter assay
The 30 UTR of SIRT1 (1420 bp) containing the SIRT1-miR-34a
response element was cloned into pMIR-REPORT Luciferase vector.
A mutant 3’UTR of SIRT1 was synthesizedby PCR, whose sequence
contained 50-ACACCCACCAAGGACCATTAGTCCGAGA-30 [18]. Cells
were plated in 24-well plates and then cotransfected with 20 nM
of either miR-34a mimics or microRNA control, 40 ng of either
pMIR-REPORT-SIRT1-WT or pMIR-REPORT-SIRT1-MUT using Lipo-
fectamine 2000. Cells were collected 48 h after transfection and
analyzed using the Dual-Luciferase Reporter Assay System (Prome-
ga, Madison, WI). Transfections were performed in triplicate and
repeated at least twice in separate experiments.
2.6. Western blots
Western blots were performed as previously described [14].
Protein concentrations were determined by Bio-Rad assay, as
directed by the manufacturer (Bio-Rad, Hercules, CA).2.7. Luciferase assay
Cells were harvested and the extracts were subjected to lucifer-
ase assay using the Luciferase Assay System (Promega). Luciferase
activity was normalized with protein concentration. Protein con-
centration was measured with BCA protein assay kit (PIERCE).
2.8. Statistical analysis
Results are expressed as mean ± S.E. Differences between
groups were analyzed by Student’s t test or one-way analysis of
variance. The statistically signiﬁcant threshold was set at P < 0.05.
3. Results
3.1. miR-34a level is signiﬁcantly increased in Tat-treated TZM-bl cells
In order to assess the role of miR-34a in Tat-induced HIV-1
transactivation, we ﬁrstly evaluated the expression of miR-34a in
Tat-treated TZM-bl cells and SupT1 T cells co-transfected with
Tat plasmid and LTR-luc plasmid by using quantitative real-time
PCR. Fig. 1A showed that miR-34a levels were signiﬁcantly
increased in Tat-treated TZM-bl cells and in SupT1 T cells co-
transfected with Tat plasmid and LTR-luc plasmid in a dose-
dependent manner. However, there was no effect on miR-34a
expression with Tat-treated naïve HeLa cells (data not shown).
100nM Tat plasmid was chosen in the following experiments.
Fig. 3. Tat induced miR-34a expression through down-regulation of SIRT1. TZM-bl
cells were co-transfected with miR-34a mimics, plasmid reporter containing wild-
type or mutant 30UTR of SIRT1. After 48 h, luciferase assay was performed and
normalized to the internal ﬁreﬂy luciferase activity. ⁄⁄P < 0.01(compared to control).
H.-S. Zhang et al. / FEBS Letters 586 (2012) 4203–4207 4205These data indicate that upregulation of miR-34a may be related to
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To study the biological role of miR-34a in Tat-induced HIV-1
transactivation, TZM-bl cells and LTR-luc plasmid-transfected
SupT1 T cells that were treated with miR-34a mimics or inhibitors
were analyzed. PMA was the positive control. The miR-34a levels
were signiﬁcantly increased in TZM-bl cells and LTR-luc plasmid-
transfected SupT1 T cells transfected with miR-34a mimics
(Fig. 1B), and upregulated miR-34a promoted Tat-induced HIV-1
transactivation (Fig. 2). Furthermore, downregulated miR-34a by
its inhibitor (Fig. 1B) inhibited Tat-induced HIV-1 transactivation
(Fig. 2). These results suggest that upregulated miR-34a positively
regulates Tat-induced HIV-1 transactivation.
3.2. miR-34a directly targets SIRT1 3’-UTR
In order to identify the target gene of miR-34a in regulating
Tat-induced HIV-1 transactivation, we searched for candidate
genes using TargetScan5.2 (http://www.targetscan.org/) and
miRBase (http://www.mirbase.org/) microRNA databases. The
SIRT1 gene is one of the predicted target genes of miR-34a. To
determine whether SIRT1 responded to miR-34a through direct
3’-UTR interaction, we cloned the 3’-UTR of SIRT1 into a reporter
plasmid downstream of the luciferase gene to generate pMIR-
report-SIRT1-WT or pMIR-report-SIRT1-MUT (with a mutant
miR-34a response element). Pre-miR-34a decreased luciferase
activity of the reporter vector pMIR-report-SIRT1-WT containing
the miR-34a response element (Fig. 3). In contrast, miR-34a has a
minimal effect on the reporter vector pMIR-report-SIRT1-MUT
with a mutated miR-34a response element. Furthermore, miR-
34a does not affect SIRT1 RNA (data not shown). Taken together,
these results indicated that SIRT1 was a direct target of miR-34a.
3.3. miR-34a promotes Tat-induced HIV-1 transactivation by
repressingSIRT1
SIRT1 is an important determinant of Tat-induced HIV-1 trans-
activation. Therefore, we speculated that the role of miR-34a in
TZM-bl cells was mediated by regulating endogenous SIRT1
expression. The effects of miR-34a mimics or inhibitors on SIRT1
RNA and protein levels were examined by Q-RT-PCR and western
blotting. MiR-34a mimics resulted in 50–70% reduction of SIRT1
protein levels in TZM-bl cells (Figs. 4A). MiR-34a inhibitors signif-
icantly upregulated SIRT1 protein levels in comparison to negativeFig. 2. miR-34a affects Tat-induced HIV-1 LTR transactivation in TZM-bl cells and
SupT1 T cells. TZM-bl cells and SupT1 T cells were transfected with mimics control,
miR-34a mimics, inhibitor control, miR-34a inhibitor and 100 nM Tat plasmid or
1 lM PMA for 48 h. Cells were collected at 48 h post-transfection and analyzed for
luciferase activity. The Y axis represents percent increase of luciferase activity
relative to the Tat alone. ## P value <0.01 compared to Tat group (n = 3).
Fig. 4. miR-34a promotes Tat-induced HIV-1 transactivation by repressing SIRT1.
(A). TZM-bl cells were transfected with mimics control, miR-34a mimics, inhibitor
control, miR-34a inhibitor or 100 nM Tat plasmid for 48 h. SIRT1 expression was
assessed by western blot. Loading control was obtained using anti-b-actin antibody.
Blots were representative of three experiments. (B) TZM-bl cells and SupT1 T cells
were transfected with mimics control, miR-34a mimics, 50nM SIRT1, 50 nM
SIRT1H363Y (SIRT1HY), 5 mM NAM, 10 lM TSA or 100 nM Tat plasmid for 48 h.
Cells were collected at 48 h post-transfection and analyzed for luciferase activity.
The Y axis represents percent increase of luciferase activity relative to the Tat alone.
## a P value <0.01 compared to Tat group (n = 3). P < 0.01(compared to
Tat + pre-miR-34a group).controls in TZM-bl cells (Fig. 4A). MiR-34a mimics or inhibitors had
no effect on SIRT1 at RNA level (data not shown).
The inhibition of SIRT1 by miR-34a was partially recovered after
co-transfection with a plasmid-expressing SIRT1. Fig. 4B showed
that Tat-induced HIV-1 transactivation was inhibited when SIRT1
was re-expressed in TZM-bl cells and SupT1 T cells transfected
with LTR-luc plasmid treated with miR-34a, while SIRT H363Y mu-
tant plasmid had no effect. While SIRT1 inhibitor nicotinamide
potentiated miR-34a-induced HIV-1 transactivation. These data
conﬁrm that miR-34a promotes Tat-induced HIV-1 transactivation,
at least in part by repressing endogenous SIRT1.
Fig. 5. Effect of miR-34a on Tat-induced NF-kB p65 acetylation in TZM-bl cells.
TZM-bl cells were transfected with (A) mimics control, miR-34a mimics, inhibitor
control, miR-34a inhibitor; (B) 5 mM NAM, 10 lM TSA or 100 nM Tat plasmid for
48 h. Ac-p65 (lysine 310) expression was assessed by western blot. Loading control
was obtained using anti-p65 antibody. Blots were representative of three
experiments.
Tat    miR-34a     SIRT1     NF-κB activation    HIV-1 transactivation 
Fig. 6. The diagram that summarize the interplay of Tat – miR34a – SIRT1 – NF – kB
pathway in the process of Tat-induced LTR transactivation. (?: activated; :
inhibited).
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Tat directly interacts with the deacetylase domain of SIRT1 and
blocks the ability of SIRT1 to deacetylate lysine 310 in the p65 sub-
unit of NF-kB and inhibited LTR transactivation [9]. As shown in
Fig. 5A, transfected with Tat plasmid cause an increase in acety-
lated lysine 310 (K310) in the p65 subunit of NF-kB in TZM-bl cells,
whereas enforced expression of miR-34a by transfection with miR-
34a mimics potentiated Tat-mediated increase in acetylated p65
(K310) in TZM-bl cells. However, silencing of miR-34a by transfec-
tion of a miR-34a inhibitor suppressed Tat-induced increase in
acetylated p65 (K310) in TZM-bl cells. Treatment with SIRT1 inhib-
itor nicotinamide potentiated Tat-mediated increase in acetylated
p65 (K310); while treated with class I and II HDAC inhibitors TSA
had no effect on Tat-mediated increase in acetylated p65 (K310)
in TZM-bl cells (Fig. 5B).
4. Discussion
Recent studies showed that miRNAs are involved in several
important biological events including HIV-1 infection. MiRNAs
are known to act as regulators in HIV-1 infection and replication
[19–21]. In the study, we ﬁrstly veriﬁed that the expression level
of miR-34a was signiﬁcantly increased in Tat-treated TZM-bl cells
and SupT1 T cells co-transfected with Tat plasmid and LTR-luc
plasmid. MiR-34a overexpression promoted Tat-induced HIV-1
transactivation, whereas its depletion decreased Tat-induced
HIV-1 transactivation. We further demonstrated that miR-34a di-
rectly targeted 30-UTR of SIRT1 gene, and inhibited its expression.
Importantly, SIRT1 re-expression reduced Tat-induced HIV-1
transactivation induced by miR-34a. These data conﬁrm that
miR-34a promoted Tat-induced HIV-1 transactivation, at least in
part by repressing endogenous SIRT1. Additionally, we found that
Tat-induced miR-34a expression affected p65 acetylation, which
was important for HIV-1 transactivation.
Cellular miRNAs can inﬂuence HIV replication in two ways: di-
rect targeting of HIV-1 RNA sequences or indirect targeting of RNAs
encoding cellular factors involved in HIV replication [22–23]. Be-cause Tat is required for productive transcription from the HIV-1
long terminal repeat (LTR) promoter, suppression of PCAF expres-
sion by miR-17-5p and miR-20a results in reduced viral transcrip-
tion and replication [24]. MiR-27b acts as a novel regulator of
Cyclin T1 protein levels which are involved in HIV-1 replication,
while miR-29b, miR-223, and miR-150 may indirectly regulate Cy-
clin T1 [22]. HIV-1 Tat protein increases the levels of miR-34a and
promotes neuronal dysfunction [25]. In the present study, Tat in-
creased the expression of miR-34a, which was consistent with
above ﬁndings. Tat-induced miR-34a expression promoted HIV-1
transactivation, which was conﬁrmed by transfected with miR-
34a mimics or miR-34a inhibitors.
The class III histone deacetylase sirtuin 1 (SIRT1) is increasingly
recognized as a critical regulator of stress responses, replicative
senescence, inﬂammation, metabolism, and aging. SIRT1 expres-
sion is regulated transcriptionally and post-transcriptionally, and
its enzymatic activity is controlled by nicotinamide adenine dinu-
cleotide (NAD+) levels and interacting proteins [26–28]. Tat also
interacts with SIRT1. Binding of Tat to SIRT1 has two effects. First,
SIRT1 deacetylates and inactivates Tat [29]. Second, Tat inhibits the
SIRT1-mediated deacetylation of the p65 subunit of NF-jB, thus
promoting the transcriptional activity of NF-jB [30]. Regulation
of HIV-1 transcription is a complex, multistage process requiring
cooperative action of both viral and cellular proteins [31]. The
LTR is regulated by viral proteins as well as host factors, including
NF-jB that becomes activated in virus-infected cells. The enhancer
region of HIV-1 LTR-promoter contains two functional active NF-
jB binding sites. NF-jB is a ubiquitous transcription factor critical
in inﬂammation and immunity [32]. Previously, various reagents
targeting the NF-jB signaling pathway have been examined for
their inhibitory effects on HIV-1 [33]. NF-jB signaling is indispens-
able for T cell activation and HIV-1 preferentially replicates in pro-
liferating CD4+ T cells, partly by taking advantage of the activated
host transcription machinery [34]. Data from previous studies
showed that miR-34a directly inhibits SIRT1, a critical regulator
of stress responses, replicative senescence, inﬂammation, metabo-
lism, and aging. We found that miR-34a inhibits Tat-induced NF-
jB activation (as monitored by acetylation of p65). These results
suggest that up-regulation of miR-34a may inﬂuence Tat-induced
HIV-1 transactivation by activation of NF-jB signaling pathway
through down-regulation of SIRT1 expression. In sum, Tat induced
up-regulation of miR-34 expression; miR-34a inhibited SIRT1
expression and thus led to an increase in acetylation of NF-jB
p65 with NF-jB activation; NF-jB activation promoted HIV-1
transactivation (Fig. 6).
In conclusion, the results of our study suggest that Tat caused
HIV-1 LTR transactivation as well as NF-jB activation via miR-
34a down-regulating SIRT1 expression. The present research could
imply that elucidating the mechanism of the signaling pathway
make it a candidate for treatment of AIDS and its associated
complications.
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